Biogen Inc. (BIIB) Next Earnings Date & Options-Implied ±7.2% Move
Biogen Inc. (BIIB) carries a Roarable Rating of C (Hold) with 64/100 RQD Confidence. The underlying business is intact, so current owners don’t need to panic-sell—but mixed big-money flow or rich pricing means new buyers can afford to wait for either a pullback or a B-or-higher upgrade.
Options-Implied Post-Earnings ±7.2% Bell Curve
Will BIIB Beat & Rip or Miss Next Quarter?
Trailing EPS: $8.75 • YoY Revenue Growth: 2.2%
Recent SEC Reported Revenue, Net Profit & Diluted EPS Cadence
| Period | Filed | Revenue | Net Profit | Free Cash Flow | Gross Margin |
|---|---|---|---|---|---|
| FY 2025 | 2025-12-31 | $9.89B | $1.29B | $2.05B | 75.7% |
| FY 2024 | 2024-12-31 | $9.68B | $1.63B | $2.72B | 76.1% |
| FY 2023 | 2023-12-31 | $9.84B | $1.16B | $1.10B | 44% |
Whale Flow & Momentum Playbook: Trading BIIB & AI Leaders Without Chasing Tops
- ✓Exact institutional whale strikes & implied earnings range on BIIB this week
- ✓How active traders scale setups using funded prop-firm accounts instead of risking savings
- ✓Free bonus: instant RQD Rating Flip alerts on all tracked momentum leaders
BIIB Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
vs. +2.2% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
No active Ellis Vennor swing setup published on BIIB today. View full Setup Ledger →
No direct multi-tier Butterfly edges indexed yet for BIIB. Explore sector supply chains on /butterfly.
BIIB Investor FAQ & Complete 8-Part Research Index
100% OPEN ACCESS • SEC EDGAR × CBOE × FREDWhen is BIIB's next earnings date?
Based on SEC filing cadence, Biogen Inc. (BIIB)'s next quarterly earnings window is estimated around Dec 30, 2026.
How much is BIIB stock expected to move on earnings?
Options markets currently imply a ±7.2% post-earnings move for BIIB, projecting a trading range between $231.68 and $267.62.